{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T18:34:55Z","timestamp":1774895695796,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12015-025-11039-8","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T07:52:52Z","timestamp":1766044372000},"page":"875-888","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Safety and Efficacy of Systemic DT-DEC01 Cell Therapy in Non-Ambulatory Duchenne Muscular Dystrophy Patients: a 24-Month Clinical Evaluation"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6372-6122","authenticated-orcid":false,"given":"Maria","family":"Siemionow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Biega\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Niezgoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Sobkowiak-Sobierajska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaros\u0142aw","family":"Czarnota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Siemionow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ziemiecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Bo\u017cyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Wachowiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"1","key":"11039_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., DMD Care Considerations Working Group. (2010). Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management. The Lancet Neurology, 9(1), 77\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(09)70271-6","journal-title":"The Lancet Neurology"},{"issue":"2","key":"11039_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10654-021-00819-4","volume":"37","author":"L Wahlgren","year":"2022","unstructured":"Wahlgren, L., Kroksmark, A. K., Tulinius, M., & Sofou, K. (2022). One in five patients with Duchenne muscular dystrophy dies from other causes than cardiac or respiratory failure. European Journal of Epidemiology, 37(2), 147\u2013156. https:\/\/doi.org\/10.1007\/s10654-021-00819-4","journal-title":"European Journal of Epidemiology"},{"key":"11039_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","volume":"16","author":"S Guiraud","year":"2015","unstructured":"Guiraud, S., Aartsma-Rus, A., Vieira, N. M., Davies, K. E., van Ommen, G. J. B., & Kunkel, L. M. (2015). The pathogenesis and therapy of muscular dystrophies. Annual Review of Genomics and Human Genetics, 16, 281\u2013308. https:\/\/doi.org\/10.1146\/annurev-genom-090314-025003","journal-title":"Annual Review of Genomics and Human Genetics"},{"issue":"6","key":"11039_CR4","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ejpn.2016.07.020","volume":"20","author":"HJA Van Ruiten","year":"2016","unstructured":"Van Ruiten, H. J. A., Marini Bettolo, C., Cheetham, T., Eagle, M., Lochmuller, H., Straub, V., Bushby, K., & Guglieri, M. (2016). Why are some patients with Duchenne muscular dystrophy dying young: An analysis of causes of death in North East England. European Journal of Paediatric Neurology, 20(6), 904\u2013909. https:\/\/doi.org\/10.1016\/j.ejpn.2016.07.020","journal-title":"European Journal of Paediatric Neurology"},{"issue":"1","key":"11039_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/0883073813517263","volume":"30","author":"DJ Fox","year":"2015","unstructured":"Fox, D. J., Kumar, A., West, N. A., DiRienzo, A. G., James, K. A., Oleszek, J., Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). (2015). Trends with corticosteroid use in males with Duchenne muscular dystrophy born 1982\u20132001. Journal of Child Neurology, 30(1), 21\u201326. https:\/\/doi.org\/10.1177\/0883073813517263","journal-title":"Journal of Child Neurology"},{"issue":"5","key":"11039_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003725.pub4","volume":"2016","author":"E Matthews","year":"2016","unstructured":"Matthews, E., Brassington, R., Kuntzer, T., Jichi, F., & Manzur, A. Y. (2016). Corticosteroids for the treatment of Duchenne muscular dystrophy. The Cochrane Database of Systematic Reviews, 2016(5), Article CD003725. https:\/\/doi.org\/10.1002\/14651858.CD003725.pub4","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"4","key":"11039_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/JND-170280","volume":"4","author":"Z Koeks","year":"2017","unstructured":"Koeks, Z., Bladen, C. L., Salgado, D., van Zwet, E., Pogoryelova, O., McMacken, G., & Lochm\u00fcller, H. (2017). Clinical outcomes in Duchenne muscular dystrophy: A study of 5345 patients from the TREAT-NMD DMD Global Database. Journal of Neuromuscular Diseases, 4(4), 293\u2013306. https:\/\/doi.org\/10.3233\/JND-170280","journal-title":"Journal of Neuromuscular Diseases"},{"key":"11039_CR8","unstructured":"FibroGen. (2023, March 6). FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy | FibroGen, Inc. investor.fibrogen.com\/news-releases. Retrieved December 1, 2025, from https:\/\/investor.fibrogen.com\/news-releases\/news-release-details\/fibrogen-announces-topline-results-lelantos-1-phase-3-clinical"},{"issue":"4","key":"11039_CR9","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3233\/JND-230019","volume":"10","author":"AM Connolly","year":"2023","unstructured":"Connolly, A. M., Zaidman, C. M., Brandsema, J. F., Phan, H. C., Tian, C., Zhang, X., & Carrier, E. (2023). Pamrevlumab, a fully human monoclonal antibody targeting connective tissue growth factor, for non-ambulatory patients with Duchenne muscular dystrophy. Journal of Neuromuscular Diseases, 10(4), 685\u2013699. https:\/\/doi.org\/10.3233\/JND-230019","journal-title":"Journal of Neuromuscular Diseases"},{"key":"11039_CR10","unstructured":"FirstWord (2024, July 29). Pfizer officially calls it quits on DMD gene therapy, lays off staff at Sanford site. Retrieved January 21, 2025, from https:\/\/firstwordpharma.com\/story\/5880030"},{"key":"11039_CR11","unstructured":"Sarepta Therapeutics (2025, June 15). Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne | Sarepta Therapeutics, Inc. Retrieved July 4, 2025, from https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-provides-safety-update-elevidys-and-initiates-steps"},{"key":"11039_CR12","unstructured":"Sarepta Therapeutics Shares Safety Update on ELEVIDYS. Saperta Therapeutics, & Retrieved (2025, March 18). June 15, 2025, from https:\/\/investorrelations.sarepta.com\/static-files\/0d505d91-6722-4528-aae0-1e99fcbc37e5"},{"key":"11039_CR13","unstructured":"Elevidys (2025, July 25). European Medicines Agency. Retrieved December 1, 2025, from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elevidys"},{"issue":"3","key":"11039_CR14","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3390\/biomedicines11030830","volume":"11","author":"A Heydemann","year":"2023","unstructured":"Heydemann, A., & Siemionow, M. (2023). A brief review of Duchenne muscular dystrophy treatment options, with an emphasis on two novel strategies. Biomedicines, 11(3), 830. https:\/\/doi.org\/10.3390\/biomedicines11030830","journal-title":"Biomedicines"},{"key":"11039_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-023-10530-4","author":"A Heydemann","year":"2023","unstructured":"Heydemann, A., Bieganski, G., Wachowiak, J., Czarnota, J., Niezgoda, A., Siemionow, K., & Siemionow, M. (2023). Dystrophin expressing chimeric (DEC) cell therapy for Duchenne muscular dystrophy: A first-in-human study with minimum 6 months follow-up. Stem Cell Reviews and Reports. https:\/\/doi.org\/10.1007\/s12015-023-10530-4","journal-title":"Stem Cell Reviews and Reports"},{"issue":"1","key":"11039_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00005-023-00691-y","volume":"71","author":"A Niezgoda","year":"2023","unstructured":"Niezgoda, A., Biega\u0144ski, G., Wachowiak, J., Czarnota, J., Siemionow, K., Heydemann, A., & Siemionow, M. (2023). Assessment of motor unit potentials duration as the biomarker of DT-DEC01 cell therapy efficacy in Duchenne muscular dystrophy patients up to 12 months after systemic-intraosseous administration. Archivum Immunologiae Et Therapiae Experimentalis, 71(1), 24. https:\/\/doi.org\/10.1007\/s00005-023-00691-y","journal-title":"Archivum Immunologiae Et Therapiae Experimentalis"},{"key":"11039_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-023-10620-3","author":"M Siemionow","year":"2023","unstructured":"Siemionow, M., Biega\u0144ski, G., Niezgoda, A., Wachowiak, J., Czarnota, J., Siemionow, K., & Heydemann, A. (2023). Safety and efficacy of DT-DEC01 therapy in Duchenne muscular dystrophy patients: A 12 - month follow-up study after systemic intraosseous administration. Stem Cell Reviews and Reports. https:\/\/doi.org\/10.1007\/s12015-023-10620-3","journal-title":"Stem Cell Reviews and Reports"},{"issue":"2","key":"11039_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s12015-017-9792-7","volume":"14","author":"M Siemionow","year":"2018","unstructured":"Siemionow, M., Cwykiel, J., Heydemann, A., Garcia-Martinez, J., Siemionow, K., & Szilagyi, E. (2018). Creation of dystrophin expressing chimeric cells of myoblast origin as a novel stem cell based therapy for Duchenne muscular dystrophy. Stem Cell Reviews and Reports, 14(2), 189\u2013199. https:\/\/doi.org\/10.1007\/s12015-017-9792-7","journal-title":"Stem Cell Reviews and Reports"},{"issue":"3","key":"11039_CR19","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12015-018-9807-z","volume":"14","author":"M Siemionow","year":"2018","unstructured":"Siemionow, M., Cwykiel, J., Heydemann, A., Garcia, J., Marchese, E., Siemionow, K., & Szilagyi, E. (2018). Dystrophin expressing chimeric (DEC) human cells provide a potential therapy for Duchenne muscular dystrophy. Stem Cell Reviews and Reports, 14(3), 370\u2013384. https:\/\/doi.org\/10.1007\/s12015-018-9807-z","journal-title":"Stem Cell Reviews and Reports"},{"issue":"6","key":"11039_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s12015-019-09916-0","volume":"15","author":"M Siemionow","year":"2019","unstructured":"Siemionow, M., Malik, M., Langa, P., Cwykiel, J., Brodowska, S., & Heydemann, A. (2019). Cardiac protection after systemic transplant of dystrophin expressing chimeric (DEC) cells to the Mdx mouse model of Duchenne muscular dystrophy. Stem Cell Reviews and Reports, 15(6), 827\u2013841. https:\/\/doi.org\/10.1007\/s12015-019-09916-0","journal-title":"Stem Cell Reviews and Reports"},{"issue":"10","key":"11039_CR21","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/sctm.21-0054","volume":"10","author":"M Siemionow","year":"2021","unstructured":"Siemionow, M., Langa, P., Harasymczuk, M., Cwykiel, J., Sielewicz, M., Smieszek, J., & Heydemann, A. (2021). Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle\u2019s function in Duchenne muscular dystrophy. Stem Cells Translational Medicine, 10(10), 1406\u20131418. https:\/\/doi.org\/10.1002\/sctm.21-0054","journal-title":"Stem Cells Translational Medicine"},{"issue":"4","key":"11039_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1089\/scd.2020.0161","volume":"30","author":"M Siemionow","year":"2021","unstructured":"Siemionow, M., Szilagyi, E., Cwykiel, J., Domaszewska-Szostek, A., Heydemann, A., Garcia-Martinez, J., & Siemionow, K. (2021). Transplantation of dystrophin expressing chimeric human cells of myoblast\/mesenchymal stem cell origin improves function in Duchenne muscular dystrophy model. Stem Cells and Development, 30(4), 190\u2013202. https:\/\/doi.org\/10.1089\/scd.2020.0161","journal-title":"Stem Cells and Development"},{"key":"11039_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-022-10384-2","author":"M Siemionow","year":"2022","unstructured":"Siemionow, M., Langa, P., Brodowska, S., Kozlowska, K., Zalants, K., Budzynska, K., & Heydemann, A. (2022). Long-term protective effect of human dystrophin expressing chimeric (DEC) cell therapy on amelioration of function of cardiac, respiratory and skeletal muscles in Duchenne muscular dystrophy. Stem Cell Reviews and Reports. https:\/\/doi.org\/10.1007\/s12015-022-10384-2","journal-title":"Stem Cell Reviews and Reports"},{"issue":"4","key":"11039_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.5114\/aic.2021.110990","volume":"18","author":"M Malik","year":"2022","unstructured":"Malik, M., Siemionow, M., Cwykiel, J., Heydemann, A., Garcia-Martinez, J., Siemionow, K., & Szilagyi, E. (2022). Intraosseous transplant of dystrophin expressing chimeric (DEC) cells improves skeletal muscle function in Mdx mouse model of Duchenne muscular dystrophy. Post\u0119py w Kardiologii Interwencyjnej = Advances in Interventional Cardiology, 18(4), 399\u2013406. https:\/\/doi.org\/10.5114\/aic.2021.110990","journal-title":"Post\u0119py w Kardiologii Interwencyjnej = Advances in Interventional Cardiology"},{"issue":"1","key":"11039_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00005-022-00656-7","volume":"70","author":"M Siemionow","year":"2022","unstructured":"Siemionow, M., Brodowska, S., Langa, P., Zalants, K., Kozlowska, K., Grau-Kazmierczak, W., & Heydemann, A. (2022). Long-term biodistribution and safety of human dystrophin expressing chimeric cell therapy after systemic-intraosseous administration to Duchenne muscular dystrophy model. Archivum Immunologiae et Therapiae Experimentalis, 70(1), 20. https:\/\/doi.org\/10.1007\/s00005-022-00656-7","journal-title":"Archivum Immunologiae et Therapiae Experimentalis"},{"issue":"3","key":"11039_CR26","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3390\/biomedicines12030586","volume":"12","author":"M Siemionow","year":"2024","unstructured":"Siemionow, M., Budzynska, K., Zalants, K., Langa, P., Brodowska, S., Siemionow, K., & Heydemann, A. (2024). Amelioration of morphological pathology in cardiac, respiratory, and skeletal muscles following intraosseous administration of human dystrophin expressing chimeric (DEC) cells in Duchenne muscular dystrophy model. Biomedicines, 12(3), 586. https:\/\/doi.org\/10.3390\/biomedicines12030586","journal-title":"Biomedicines"},{"issue":"5","key":"11039_CR27","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3390\/biom14050575","volume":"14","author":"K Budzynska","year":"2024","unstructured":"Budzynska, K., Siemionow, M., Stawarz, K., Chambily, L., & Siemionow, K. (2024). Chimeric cell therapies as a novel approach for Duchenne muscular dystrophy (DMD) and muscle regeneration. Biomolecules, 14(5), 575. https:\/\/doi.org\/10.3390\/biom14050575","journal-title":"Biomolecules"},{"issue":"5","key":"11039_CR28","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/dmcn.12938","volume":"58","author":"E Landfeldt","year":"2016","unstructured":"Landfeldt, E., Lindgren, P., Bell, C. F., Guglieri, M., Straub, V., Lochm\u00fcller, H., & Bushby, K. (2016). Health-related quality of life in patients with Duchenne muscular dystrophy: A multinational, cross-sectional study. Developmental Medicine & Child Neurology, 58(5), 508\u2013515. https:\/\/doi.org\/10.1111\/dmcn.12938","journal-title":"Developmental Medicine & Child Neurology"},{"key":"11039_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1360385","author":"L Ju\u0159\u00edkov\u00e1","year":"2024","unstructured":"Ju\u0159\u00edkov\u00e1, L., Mas\u00e1rov\u00e1, L., Panovsk\u00fd, R., Pe\u0161l, M., Revendov\u00e1, K. \u017d, Voln\u00fd, O., & Podolsk\u00e1, K. (2024). Decreased quality of life in Duchenne muscular disease patients related to functional neurological and cardiac impairment. Frontiers in Neurology. https:\/\/doi.org\/10.3389\/fneur.2024.1360385","journal-title":"Frontiers in Neurology"},{"issue":"10329","key":"11039_CR30","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(22)00012-5","volume":"399","author":"CM McDonald","year":"2022","unstructured":"McDonald, C. M., Marb\u00e1n, E., Hendrix, S., Hogan, N., Ruckdeschel Smith, R., Eagle, M., & Rogers, R. G. (2022). Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 399(10329), 1049\u20131058. https:\/\/doi.org\/10.1016\/S0140-6736(22)00012-5","journal-title":"Lancet"},{"key":"11039_CR31","unstructured":"Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy (2025, July 11). Capricor Therapeutics, Inc. Retrieved December 1, 2025, from https:\/\/www.capricor.com\/investors\/news-events\/press-releases\/detail\/319\/capricor-therapeutics-provides-regulatory-update-on"},{"key":"11039_CR32","unstructured":"Global Lung Function Initiative (2021). (2021). Global Lung Function Initiative calculator. GLI calculator. Retrieved October 20, 2025, from https:\/\/gli-calculator.ersnet.org\/index.html"},{"key":"11039_CR33","doi-asserted-by":"crossref","unstructured":"Siemionow, M., Bieganski, G., Wachowiak, J., Czarnota, J., Siemionow, K., Niezgoda,A., \u2026 Heydemann, A. (2025). Safety and Efficacy of DT\u2013DEC01 Therapy in Non-Ambulatory Duchenne Muscular Dystrophy Patients up to 24 Months after Systemic Administration.Presented at the 2025 MDA Clinical & Scientific Conference, 2025 MDA Clinical & Scientific Conference, Dallas, TX, USA.","DOI":"10.1097\/01.tp.0001123892.14228.3c"},{"issue":"1","key":"11039_CR34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13023-021-01862-w","volume":"16","author":"SM Szabo","year":"2021","unstructured":"Szabo, S. M., Salhany, R. M., Deighton, A., Harwood, M., Mah, J., & Gooch, K. L. (2021). The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: A systematic literature review. Orphanet Journal of Rare Diseases, 16(1), 237. https:\/\/doi.org\/10.1186\/s13023-021-01862-w","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"4","key":"11039_CR35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant, D. J., Bushby, K., Bann, C. M., Alman, B. A., Apkon, S. D., Blackwell, A., & Ward, L. M. (2018). Diagnosis and management of Duchenne muscular dystrophy, part 2: Respiratory, cardiac, bone health, and orthopaedic management. The Lancet Neurology, 17(4), 347\u2013361. https:\/\/doi.org\/10.1016\/S1474-4422(18)30025-5","journal-title":"The Lancet Neurology"},{"issue":"7","key":"11039_CR36","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s12015-024-10756-w","volume":"20","author":"M Siemionow","year":"2024","unstructured":"Siemionow, M., Bocian, K., Bozyk, K. T., Ziemiecka, A., & Siemionow, K. (2024). Chimeric cell therapy transfers healthy donor mitochondria in Duchenne muscular dystrophy. Stem Cell Reviews and Reports, 20(7), 1819\u20131829. https:\/\/doi.org\/10.1007\/s12015-024-10756-w","journal-title":"Stem Cell Reviews and Reports"},{"issue":"9","key":"11039_CR37","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.3390\/biomedicines12091996","volume":"12","author":"M Siemionow","year":"2024","unstructured":"Siemionow, M., Ziemiecka, A., Bo\u017cyk, K., & Siemionow, K. (2024). Mechanisms of chimeric cell therapy in Duchenne muscular dystrophy. Biomedicines, 12(9), 1996. https:\/\/doi.org\/10.3390\/biomedicines12091996","journal-title":"Biomedicines"},{"issue":"2","key":"11039_CR38","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1017\/S1047951119002610","volume":"30","author":"KA James","year":"2020","unstructured":"James, K. A., Gralla, J., Ridall, L. A., Do, T. N., Czaja, A. S., Mourani, P. M., & Auerbach, S. R. (2020). Left ventricular dysfunction in Duchenne muscular dystrophy. Cardiology in the Young, 30(2), 171\u2013176. https:\/\/doi.org\/10.1017\/S1047951119002610","journal-title":"Cardiology in the Young"},{"issue":"2","key":"11039_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3233\/JND-180351","volume":"6","author":"N Khan","year":"2019","unstructured":"Khan, N., Eliopoulos, H., Han, L., Kinane, T. B., Lowes, L. P., Mendell, J. R., & McDonald, C. M. (2019). Eteplirsen treatment attenuates respiratory decline in ambulatory and non-ambulatory patients with Duchenne muscular dystrophy. Journal of Neuromuscular Diseases, 6(2), 213\u2013225. https:\/\/doi.org\/10.3233\/JND-180351","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"4","key":"11039_CR40","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00005-015-0380-8","volume":"64","author":"M Hivelin","year":"2016","unstructured":"Hivelin, M., Klimczak, A., Cwykiel, J., Sonmez, E., Nasir, S., Gatherwright, J., & Siemionow, M. (2016). Immunomodulatory effects of different cellular therapies of bone marrow origin on chimerism induction and maintenance across MHC barriers in a face allotransplantation model. Archivum Immunologiae Et Therapiae Experimentalis, 64(4), 299\u2013310. https:\/\/doi.org\/10.1007\/s00005-015-0380-8","journal-title":"Archivum Immunologiae Et Therapiae Experimentalis"},{"issue":"1","key":"11039_CR41","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.transproceed.2004.12.216","volume":"37","author":"MZ Siemionow","year":"2005","unstructured":"Siemionow, M. Z., Klimczak, A., & Unal, S. (2005). Different routes of donor-derived hematopoietic stem cell transplantation for donor-specific chimerism induction across MHC barrier. Transplantation Proceedings, 37(1), 62\u201364. https:\/\/doi.org\/10.1016\/j.transproceed.2004.12.216","journal-title":"Transplantation Proceedings"},{"issue":"5","key":"11039_CR42","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/j.transproceed.2005.03.127","volume":"37","author":"M Siemionow","year":"2005","unstructured":"Siemionow, M., Zielinski, M., Ozmen, S., & Izycki, D. (2005). Intraosseus transplantation of donor-derived hematopoietic stem and progenitor cells induces donor-specific chimerism and extends composite tissue allograft survival. Transplantation Proceedings, 37(5), 2303\u20132308. https:\/\/doi.org\/10.1016\/j.transproceed.2005.03.127","journal-title":"Transplantation Proceedings"},{"issue":"5","key":"11039_CR43","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.transproceed.2005.03.054","volume":"37","author":"M Siemionow","year":"2005","unstructured":"Siemionow, M., Ozer, K., Izycki, D., Unsal, M., & Klimczak, A. (2005). A new method of bone marrow transplantation leads to extention of skin allograft survival. Transplantation Proceedings, 37(5), 2309\u20132314. https:\/\/doi.org\/10.1016\/j.transproceed.2005.03.054","journal-title":"Transplantation Proceedings"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-025-11039-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-025-11039-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-025-11039-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:16:45Z","timestamp":1769750205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12015-025-11039-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["11039"],"URL":"https:\/\/doi.org\/10.1007\/s12015-025-11039-8","relation":{},"ISSN":["2629-3269","2629-3277"],"issn-type":[{"value":"2629-3269","type":"print"},{"value":"2629-3277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Freely-given, written informed consent to participate in the study was obtained from all participants (or their parent or legal guardian in the case of children under 16). The tissues were obtained in MedPolonia Hospital (Poznan, Poland). No tissues were obtained from prisoners.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Freely-given, written informed consent for publication was obtained from all participants (or their parent or legal guardian in the case of children under 16).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Bioethics Committee at the Regional Medical Council in Poznan, Poland (no. 46\/2019).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}},{"value":"M.S. is CMO and shareholder of Dystrogen Therapeutics Corp. the company that holds a license for DT-DEC01 therapy. M.S. is the inventor on the patent application filed by University of Illinois at Chicago related to chimeric cell therapy for Duchenne muscular dystrophy (WO\/2016\/201182). The author declares a potential conflict of interest. K.S. is CEO and shareholder of Dystrogen Therapeutics Corp. The author declares a potential conflict of interest. G.B., A.N., A.S.-S., J.C., and J.W. received fees for work related to this study. A.Z. and K.B. are Dystrogen Therapeutics Corp. employees.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}